72c16603-1f6c-479c-8cf0-95d499f328be
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.320
- WNT_BETA_CATENIN_SIGNALING+0.290
- CHOLESTEROL_HOMEOSTASIS+0.240
- OXIDATIVE_PHOSPHORYLATION+0.190
- BILE_ACID_METABOLISM+0.180
- PEROXISOME+0.180
- DNA_REPAIR+0.170
- KRAS_SIGNALING_DN+0.160
- XENOBIOTIC_METABOLISM+0.160
- FATTY_ACID_METABOLISM+0.110
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.470
- ANGIOGENESIS-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.350
- PROTEIN_SECRETION-0.340
- UV_RESPONSE_DN-0.340
- ALLOGRAFT_REJECTION-0.330
- APOPTOSIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5cfccf66-7f7d-4385-96c8-8628a3cdbecb | — | — | 0.858 |
| 2 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.849 |
| 3 | cf37eb41-0595-4a82-a65b-3058902a48d4 | — | — | 0.842 |
| 4 | 124c158a-8435-4f81-b84e-89ccc4bb53f1 | — | — | 0.829 |
| 5 | SRR25043618 | — | — | 0.828 |
| 6 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.823 |
| 7 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.823 |
| 8 | MNG662 | — | — | 0.819 |
| 9 | MDT-AP-1250 | Med | Medulloblastoma | 0.816 |
| 10 | SRR25043617 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |